Business Context and Reporting Period
This Form 8-K filing by Drugs Made In America Acquisition Corp. (DMAA) covers events occurring between February 12, 2026, and February 28, 2026, with the report dated March 6, 2026. The filing addresses significant governance changes triggered by financial irregularities involving the company's Sponsor and an affiliate entity, Drugs Made In America Acquisition II Corp.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, or margins for the reporting period. However, it discloses specific financial irregularities regarding the Affiliate's working capital account:
- Total Withdrawal: The Sponsor withdrew an aggregate of $1,100,000 from the Affiliate's working capital account between September 26, 2025, and September 30, 2025.
- Allocation of Funds: $325,000 was used to repay a working capital note to the Sponsor, and $208,000 was used to repay offering costs.
- Overpayment Amount: An additional $566,269 was identified as an overpayment to the Sponsor. Between September 30, 2025, and December 31, 2025, the Sponsor withdrew an additional amount of no less than $200,000 for expenses unrelated to the Affiliate.
- Repayment Status: As of February 12, 2026, the Sponsor was unable to repay the Overpayment Amount.
Material Changes
The primary material change reported is the departure of senior leadership and the appointment of a new CEO due to the Sponsor's inability to return misappropriated funds.
- Resignation and Removal: Lynn Stockwell resigned and was subsequently removed as Chief Executive Officer, Executive Chair of the Board, and Board member of both the Company and the Affiliate, effective February 28, 2026.
- Appointment: Roger Bendelac was appointed as the new Chief Executive Officer, effective February 28, 2026.
Outlook, Risks, and Management Commentary
Management Commentary: The Board of Directors acted to remove Ms. Stockwell and appoint Mr. Bendelac in response to the Sponsor's conduct and the failure to repay the Overpayment Amount. Mr. Bendelac brings over 30 years of experience in investment banking and corporate advisory.
Compensation: Mr. Bendelac's compensation has not yet been determined; the Board intends to approve an arrangement at a future date.
Risks and Contingencies: The filing highlights a significant governance risk stemming from the Sponsor's withdrawal of funds for unrelated expenses and the subsequent inability to repay the Affiliate. This situation necessitated immediate executive turnover.
Investor Verification Checklist
- Verify the status of the $566,269 overpayment and the additional $200,000+ withdrawal from the Affiliate's working capital account.
- Confirm the terms of the new compensation arrangement for CEO Roger Bendelac once disclosed.
- Review the relationship and financial standing of the Sponsor to assess the risk of further fund withdrawals.
- Monitor future filings for any legal actions taken against the Sponsor or former CEO regarding the misappropriated funds.